Wedelolactone suppresses breast cancer growth and metastasis via regulating TGF-β1/Smad signaling pathway

Objective: Breast Cancer is a malignant tumor with high invasion and metastasis. TGF-β1-induced epithelial-mesenchymal transition (EMT) is crucially involved in the growth and metastasis of breast Cancer. Wedelolactone (Wed) is extracted from herbal medicine Ecliptae Herba, which is reported to have antineoplastic activity. Here, we aimed to elucidate the efficacy and mechanism of Wed against breast Cancer.

Methods: The effects of Wed on migration and invasion of 4T1 were detected. The expression of EMT-related markers was detected by Western blot and qPCR. The 4T1 orthotopic murine breast Cancer model was established to evaluate the therapeutic effect of Wed on the growth and metastasis of breast Cancer through TGF-β1/Smad pathway.

Results: Wed inhibited the proliferation, migration and invasion of 4T1. It exhibited concentration-dependent inhibition of p-Smad2/3. Wed also reversed the expression of EMT-markers induced by TGF-β1. In addition, Wed suppressed the growth and metastasis of breast Cancer in mice. It also affected p-Smad3 expression as well as EMT-related genes, suggesting that its anti-breast Cancer effect may be related to the TGF-β1/Smad pathway.

Conclusion: Wed reverses EMT by regulating TGF-β1/Smad pathway, potentially serving as a therapeutic agent for breast Cancer. Wed is expected to be a potential drug to inhibit TGF-β1/Smad pathway-related diseases.

TGF-β1/Smad signaling pathway; breast cancer; epithelial-mesenchymal transition; lung metastasis; wedelolactone.